Clinically considerable immune-mediated hematologic adverse reactions (including hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) transpired at an incidence of a lot less than one% in patients who been given this drug or ended up reported with the use of other PD-1/PD-L1 blocking